The company is currently conducting a Phase 2 clinical study for diffuse systemic sclerosis, a rare autoimmune disease. They are also planning Phase 2 studies for chronic kidney disease and focal segmental glomerulosclerosis, both of which lead to kidney failure. Certa Therapeutics uses genetic analysis to identify patients who are most likely to benefit from their therapies, addressing a market worth around US$5 billion per year. Their goal is to provide pre-emptive treatment for fibrotic diseases, such as kidney fibrosis, and expand their drug development to other disease states characterized by inflammation and fibrosis.